Core Viewpoint - The company, Awei Technology Co., Ltd., is making a strategic investment of 10 million RMB in Hunan Luying Technology Co., Ltd., acquiring a 9.0744% stake, which aligns with its long-term development goals and aims to enhance its competitive edge in the medical imaging sector [2][13][14]. Investment Overview - The total investment amount for this round is 30 million RMB, with Awei Technology contributing 10 million RMB to subscribe for 249.3766 thousand RMB of the new registered capital of Luying Technology [4][8]. - The investment does not require board or shareholder approval as it falls within the general manager's authority and has completed internal decision-making processes [5][14]. Target Company Information - Hunan Luying Technology Co., Ltd. specializes in the development of high-resolution single-photon emission computed tomography (SPECT) and its core components, aiming to provide advanced molecular imaging diagnostic solutions [6][13]. - The company was established less than a year ago and currently does not have any sales revenue or profit [6][16]. Market Context - The global medical imaging and radiation therapy equipment market is experiencing rapid and stable growth, with significant government support for the domestic nuclear medicine industry, particularly in promoting the localization of nuclear medicine imaging equipment [13][14]. - SPECT/CT technology is recognized for its clinical value in early cancer diagnosis and has a strong market outlook, making it a strategic area for investment [13][14]. Strategic Implications - This investment is expected to deepen synergies within the company's main business and enhance its overall competitiveness, aligning with its strategic development plans [13][14]. - The funding for this investment comes from the company's own resources and will not adversely affect its normal operations or financial status [14]. Future Considerations - The success of this investment will depend on Luying Technology's future operational performance and its ability to navigate various risks associated with market conditions, technology development, and regulatory approvals [16].

Core Viewpoint - The company, Awei Technology Co., Ltd., has announced a voluntary disclosure regarding its investment in Hunan Luying Technology Co., Ltd., indicating a strategic move to enhance its business capabilities and market position in the medical imaging sector [1][14]. Investment Overview - The investment target is Hunan Luying Technology Co., Ltd., with an investment amount of RMB 10 million, resulting in a 9.0744% equity stake in Luying Technology after the capital increase [1][3]. - The total investment for this round is RMB 30 million, with Awei contributing RMB 10 million, and the investment is approved within the general manager's authority, not requiring board or shareholder approval [3][4]. - The investment does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [1][5]. Target Company Information - Hunan Luying Technology Co., Ltd. is focused on developing high-resolution single-photon emission computed tomography (SPECT) and its core components, aiming to provide advanced molecular imaging diagnostic solutions [5][14]. - The company was established less than a year ago and currently does not have sales revenue or profitability, with its core product still under development [5][14]. Strategic Importance - The investment aligns with the company's strategic development plan, aiming to strengthen its core business while seeking new growth opportunities in the rapidly growing medical imaging and radiation therapy equipment market [14][15]. - The SPECT/CT technology is recognized for its clinical value in early cancer diagnosis and has significant market potential, supported by government policies promoting the domestic development of nuclear medicine equipment [14][15]. Financial Impact - The investment is expected to enhance the company's overall competitiveness and is made using the company's own funds, ensuring no adverse impact on its financial status or operations [15]. - The long-term benefits of the investment will depend on Luying Technology's future operational performance [15].

Core Viewpoint - Awei Technology plans to invest 10 million yuan in Hunan Luying Technology Co., Ltd., marking its entry into the high-end nuclear medicine imaging equipment sector [1][2]. Investment Details - Awei Technology will invest 10 million yuan, participating in a total capital increase of 30 million yuan alongside other investors [1]. - After the investment, Awei Technology will hold a 9.07% stake in Luying Technology [1]. - The investment decision was made within the general manager's approval authority, requiring no board or shareholder meeting approval [1]. Company Background - Luying Technology, established on April 29, 2025, focuses on the development of domestic high-resolution single-photon emission computed tomography (SPECT) and its core components [1][3]. - The company aims to provide precise, safe, economical, and convenient molecular imaging diagnostic solutions [3]. Market Context - The global medical imaging and radiotherapy equipment market is experiencing rapid and stable growth [2]. - Government policies are promoting the domestic production of nuclear medicine imaging equipment, supporting the industry's development [2]. Product and Technology Insights - SPECT/CT is recognized for its clinical value in early diagnosis and evaluation of tumors, as well as its importance in cardiovascular, bone, and neurological imaging [2]. - Luying Technology's project team has experience in obtaining regulatory approval for SPECT/CT devices and holds core intellectual property, positioning it at an advanced level domestically [3]. Management and Ownership - The controlling shareholders of Luying Technology include key figures from Hunan University, indicating a strong academic and technical foundation [3]. - The company currently has no sales revenue and is still in the product development phase, which presents uncertainties regarding future profitability [3].